Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (TRuE-CHE2): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema

NCT05233410 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05233410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (TRuE-CHE2): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Withdrawn
Start date
January 31, 2023
Completion date
September 22, 2024
Enrollment
0 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand eczema (che)